| Events occurring after the reporting period |
| 25. |
Events
occurring after the reporting period |
There
were no significant events that occurred after the financial period ended December 31, 2025, which require adjustment to the financial
statements.
However,
the following non-adjusting events occurred subsequent to the reporting period:
| |
a) |
In
January 2026, Atlas Medical Concierge Pte Ltd was incorporated with Basel Medical Group Pte Ltd holding 51% of the ordinary shares. |
| |
|
|
| |
b) |
On
January 22, 2026, Nasdaq determined that the Company’s ordinary shares did not comply with the minimum $1 bid price requirement
based upon the closing bid price for the last 30 consecutive business days. The Company was given a compliance period of 180 calendar
days to regain compliance. |
|
| 28. |
Events occurring after the reporting period |
There
were no significant events that occurred after the financial year ended June 30, 2025, which require adjustment to the financial statements.
However,
the following non-adjusting events occurred subsequent to the reporting period:
| a) | In
July 2025, the Company has appointed NLA DFK Assurance PAC as its new auditor, in place of
Onestop Assurance PAC. |
| b) | In
July 2025, the Company has put on hold the plan for the acquisition of Bitcoin in exchange
for the issue of ordinary shares in the Company. |
| c) | In
July 2025, Basel Medical Group Pte Ltd has made 60% investments in SSOC Novena Pte. Ltd.,
SSOC Orchard Pte. Ltd. and SSOC Farrer Park Pte. Ltd. In September 2025, 7% of these investments
in each of the 3 companies has been sold to external party, such that the company holds 53%
of the share capital in each of the 3 companies. |
| d) | In
July 2025, the Company’s subsidiary, Pharma Avenue Pte Ltd, increased its share capital
to 100,000 shares. |
| e) | In
August 2025, Mr Tan Boon Chye (Darren) was appointed as the Chief Commercial Officer of the
Company. In the same month, Mr Vincent Teo resigned as Chief Partnership Officer from the
Company. |
| f) | In September 2025, the Company’s subsidiary, Bethesda Medical Pte
Ltd, has fully disposed its investment in associate company, Cereza Bethesda Medical Pte Ltd. |
| g) | In October 2025, Chartered Imaging Pte Ltd was incorporated with Basel
Medical Group Pte Ltd holding 100% of the ordinary shares. |
| h) | In October 2025, Basel Medical Group Pte Ltd has obtained a S$3,000,000
term loan facility for a 3 year tenor. |
| i) | The major shareholder, Rainforest Capital VCC has agreed to provide financial
support for at least 12 months from the date of the auditor’s report. |
| | | |
| | j) | In December 2025, Lucky Pet Service Pte Ltd was incorporated with Basel
Medical Group Pte Ltd holding 10% of the ordinary shares. |
| | | |
| | k) | In January 2026, Atlas Medical Concierge Pte Ltd was incorporated with
Basel Medical Group Pte Ltd holding 51% of the ordinary shares. |
| | | |
| | l) | In addition to the sale and purchase agreement entered with Silkroute Biomed
Healthcare Pte. Ltd. for the acquisition of all of the ordinary shares in the issued and paid-up share capital of Bethesda Medical Pte.
Ltd in April 2025, a waiver letter with Silkroute Biomed Healthcare Pte. Ltd. was signed in October 2025. The remaining deferred consideration
of USD1,500,000 shall be waived. Following such agreement, the total consideration of US$6.5 million for the acquisition of Bethesda Medical
has been fully satisfied. |
| | | |
| | m) | On January 22, 2026, Nasdaq has determined that the Company’s common
stock does not comply with the minimum $1 bid price requirement based upon the closing bid price for the last 30 consecutive business
days. The Company has been given a compliance period of 180 calendar days to regain compliance. |
|